We often offer these patients a clinical trial, if one is available. Unfortunately, platinum resistant ovarian cancers have low response rates to chemotherapy, and clear cell cancers are particularly resistant. Doxil, weekly paclitaxel, gemcitabine, and bevacizumab are all reasonable options.